FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMicroba Life Sciences Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MAP.AX
Microba Life Sciences Limited Stock AnalysisComprehensive stock analysis for Microba Life Sciences Limited (MAP.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMAP.AX
MAP.AX
Microba Life Sciences Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MAP.AX
  1. Home
  2. Stocks
  3. Microba Life Sciences Limited

Microba Life Sciences Limited

🇦🇺MAP.AX•ASX

Microba Life Sciences Limited

🇦🇺MAP.AX•ASX

Your view on MAP.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Microba Life Sciences Limited

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Luke Reid
Headquarters
324 Queen Street, Brisbane, QLD, AU
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Luke Reid
Headquarters
324 Queen Street, Brisbane, QLD, AU
Description

Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services.

These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science.

Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers.

Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Microba Life Sciences Limited. Starting points for Microba Life Sciences Limited: EPS -AUD 0.03, beta 2.06 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Microba Life Sciences Limited. Microba Life Sciences Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Microba Life Sciences Limited. Trailing twelve-month EPS for Microba Life Sciences Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterSep 2025Next quarterDec 2025This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.00−AUD 0.01−AUD 0.02−AUD 0.01
Lowest estimateAUD 0.00−AUD 0.01−AUD 0.02−AUD 0.01
Highest estimateAUD 0.00−AUD 0.01−AUD 0.02−AUD 0.01
Number of analysts0111
A year ago——−AUD 0.031—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterSep 2025Next quarterDec 2025This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 8.29MAUD 8.20MAUD 15.36MAUD 19.78M
Lowest estimateAUD 8.29MAUD 8.20MAUD 15.36MAUD 19.78M
Highest estimateAUD 8.29MAUD 8.20MAUD 15.36MAUD 19.78M
Number of analysts1111
A year ago——AUD 14.76M—
Growth vs a year ago——+4.1%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Microba Life Sciences Limited. Microba Life Sciences Limited has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MAP.AX20 companies
Compare MAP.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
BDX.AXBCAL Diagnostics LimitedHealthcareMedical - Diagnostics & Research—
EMD.AXEmyria LimitedHealthcareMedical - Healthcare Information Services—
EYE.AXNova Eye Medical LimitedHealthcareMedical - Devices—
HMD.AXHeraMED LimitedHealthcareMedical - Devices—
IDT.AXIDT Australia LimitedHealthcareDrug Manufacturers - Specialty & Generic—
IIQ.AXINOVIQ LtdHealthcareMedical - Diagnostics & Research—
NOX.AXNoxopharm LimitedHealthcareBiotechnology—
More Medical - Diagnostics & Research companies
TickerTypeCompanySectorExchangeMkt cap
GSS.AXGenetic Signatures LimitedHealthcareASX—
HLS.AXHealius LimitedHealthcareASX—
HTGMQHTG Molecular Diagnostics, Inc.HealthcareOTC$221
IBX.AXImagion Biosystems LimitedHealthcareASX—
IBXXFImagion Biosystems LimitedHealthcareOTC$2.2M
ICBUiMD Companies, Inc.HealthcareOTC$7.7M
ICLRICON Public Limited CompanyHealthcareNASDAQ$14.6B
IDGXFIntegrated Diagnostics Holdings plcHealthcareOTC$372.0M
IDX.AXIntegral Diagnostics LimitedHealthcareASX—
IDXGInterpace Biosciences, Inc.HealthcareOTC$7.7M
IDXXIDEXX Laboratories, Inc.HealthcareNASDAQ$55.0B
IHTIIntegrative Health Technologies, Inc.HealthcareOTC$32,514
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Microba Life Sciences Limited. Coverage tracks Microba Life Sciences Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Microba Life Sciences Limited.

MAP.AX AnalysisFair
Past
1
Growth
5
Health
5
Profit
1
Value
1